Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2019-06-11 Interim / Quarterly Rep…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2019
2019-06-11 English
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes a base prospectus and a sales agreement prospectus for offering up to $100 million of various securities. This is a capital raising and financing document, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement for securities issuance. Therefore, it fits the category of Capital/Financing Update filings.
2019-06-11 English
FORM 8K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 23, 2019, for Anixa Biosciences, Inc. It specifically mentions that the report includes a corporate presentation used at an institutional investor conference. The key item is Item 7.01 Regulation FD Disclosure, which states that the presentation is attached as Exhibit 99.1. The document is short (3033 characters) and primarily serves to file the presentation material rather than a full report or financial statements. According to the filing definitions, a presentation used for investors focusing on financials, strategy, and market position fits the category of Investor Presentation (IP). Therefore, the document should be classified as an Investor Presentation (IP).
2019-05-23 English
PRIMARY DOCUMENT
Director's Dealing
2019-05-02 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-29 English
PRIMARY DOCUMENT
Director's Dealing
2019-04-29 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.